Home
You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.
Latest Food Articles
Popular Food Articles
Highly Recommended Food Articles
Email to a Friend
Send a link to this page to your friends and colleagues.
Northern California's Biggest County Sues Glaxo Over Avandia
The lawsuit is the first time that a government entity has entered court against Glaxo.
Santa Clara County, the largest county in Northern California (nearly 1.9 million people), has filed a federal lawsuit against pharmaceutical company GlaxoSmithKline, alleging that Glaxo knowingly sold its type 2 diabetes drug Avandia for several years despite indications the drug causes heart attacks and strokes.
Avandia, which began selling in 1999 and has been a major source of revenue for Pennsylvania-based Glaxo, has been under fire in recent years as evidence accumulated that the drug has been a major factor in thousands of deaths from cardiovascular events. (This Diabetes Health article discusses recent news surrounding Avandia in more detail.)
The county's lawsuit is the first time that a government entity has entered court against Glaxo. Santa Clara, which spent $2 million on Avandia from 1999 through 2007 for indigent patients, is claiming that Glaxo's silence about harmful side effects forced the county to have to spend more money, unknowingly, to treat the heart problems Avandia caused.
The county says that while it has been planning the lawsuit for some time, a recent U.S. Senate subcommittee report criticizing both Glaxo and the Food and Drug Administration for their handling of Avandia's problems was the final spur to action.
Santa Clara's suit seeks compensation not only for itself but also for California diabetes patients and healthcare providers who have used or prescribed Avandia.
Avandia is Glaxo's trade name for rosiglitazone, a member of the family of anti-diabetes drugs known as thiazolidinediones. TZDs are drugs that increase the body's sensitivity to insulin.
* * *
Source:
Categories: Diabetes, Diabetes, Food, Health Insurance, Insulin, Medications, Medications Research, Type 2 Issues
You May Also Be Interested In...
-
Diabetes Health
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.
-
Topics
- Diabetic / Diabetes Health
- Type 1 / 1.5 Diabetes
- Type 2 Diabetes
- Blood Glucose / Sugar
- High/Low Blood Sugar / Fast Acting Glucose
- Insulin- Pumps, Pens & Syringes
- Continuous Glucose Monitors, CGM, Infusion Sets
- Type 2 Medications
- Hyperglycemia
- Hypoglycemia
Comments
Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.
When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.
For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.
Don't have your Diabetes Health Username? Register now and add your comments to all our content.
Register...
Register your Diabetes Health Username here.
Have Your Say...